Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00242190 · ClinicalTrials.gov registry record · Phase 1
Gemcitabine, Oxaliplatin and Radiation Therapy in Pancreatic Cancer
A Phase 1 study, sponsored by University of Michigan Rogel Cancer Center.
- Completed
- Registry status
- Phase 1
- Development phase
- 40
- Enrollment target
NCT00242190 is a Phase 1 study that has completed, run by University of Michigan Rogel Cancer Center. The registered enrollment target is 40 participants.
The verdict
NCT00242190, a Phase 1 study, has completed, sponsored by University of Michigan Rogel Cancer Center.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 40 participants
- Enrollment target
Study Summary
This study will examine a proposed research treatment which evaluates the addition of oxaliplatin, a chemotherapy agent, to gemcitabine, another chemotherapy agent, and radiation therapy for the treatment of patients with pancreatic cancer. The researchers have already done studies using gemcitabine and radiation therapy together. They want to build on the information they have from this previous research. The researchers believe that the combination chemotherapy with radiation is worth investigating to treat pancreatic cancer. They will use this study to determine what type of side effects occur with this treatment and to assess how effective the treatment is at controlling the cancer.
Interventions
- DRUG oxaliplatin
- DRUG gemcitabine
- PROCEDURE radiation therapy
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 2004-06 |
| Est. Completion | 2010-02 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00242190
The ClinicalTrials.gov registry entry for NCT00242190 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 40 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Michigan Rogel Cancer Center, which has 292 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which oxaliplatin is the first listed.
NCT00242190 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00242190 about?
NCT00242190 is a clinical study titled "Gemcitabine, Oxaliplatin and Radiation Therapy in Pancreatic Cancer". This study will examine a proposed research treatment which evaluates the addition of oxaliplatin, a chemotherapy agent, to gemcitabine, another chemotherapy agent, and radiation therapy for the treatment of patients with pancreatic cancer. The researchers have already done studies using gemcitabine...
What is the current status of trial NCT00242190?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 40 participants. The study started on 2004-06. Estimated completion is 2010-02.
What interventions are being tested in trial NCT00242190?
The interventions under investigation include: oxaliplatin (DRUG), gemcitabine (DRUG), radiation therapy (PROCEDURE).
Who is sponsoring clinical trial NCT00242190?
This trial is sponsored by University of Michigan Rogel Cancer Center, which has 292 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.